Effects of external electrical stimulation on laser-beam-induced experimental thrombosis.
External electrical stimulation (EES) has demonstrated venous antithrombotic properties. The aim of this investigation was to study its antithrombotic properties using unfractionated heparin (UFH) as a reference in arterial and venous mesenteric microvessels. For this purpose a rat model of laser-beam-induced thrombosis was used. Four groups of rats were investigated (n = 7): control, UFH (5 mg /kg), UFH (2.5 mg/kg) and electrical stimulation [e-vascular, E = 10, alternate polarity, in two protocols: (i) 30 min before and during thrombosis induction and (ii) only 30 min before thrombosis induction as preventive stimulation]. This effect was tested in arterial and venous microvessels in the four groups using the continuous protocol and only in arterial microvessels using the preventive protocol. Three parameters were studied: the number of laser beams needed to induce platelet thrombus formation, the number of emboli and the duration of embolization. Induced hemorrhagic time (IHT), platelet aggregation induced by ADP and coagulation tests (activated partial thromboplastin time, aPTT, prothrombin time, pTT, and fibrinogen level) were also determined. Continuous electrical stimulation decreased the number of emboli and the duration of embolization both in arterioles and in venules. It also significantly reduced the amplitude and velocity of the ex vivo platelet aggregation induced by ADP. Contrary to UFH, neither aPTT nor pTT were affected in platelet-poor plasma collected after the induction of thrombosis by laser beam, nor did it modify IHT. Preventive electrical stimulation produced similar results with fewer effects on induced venous thrombosis. These data suggest that EES has a potent antithrombotic effect on arterial and venous thrombosis without any hemorrhagic adverse effects, making it a very promising tool in the prevention and treatment of venous and arterial thromboembolic complications.
Aguejouf
O
O
Laboratoire d'hématologie, UFR de pharmacie, Université Victor Ségalen, Bordeaux, France.
Doutremepuich
F
F
Doutremepuich
C
C
D000818:Animals; D001158:Arteries; D001780:Blood Coagulation Tests; D004195:Disease Models, Animal; D004599:Electric Stimulation Therapy / Q000379:methods*; D006493:Heparin / Q000592:standards / Q000627:therapeutic use; D007834:Lasers / Q000009:adverse effects*; D008297:Male; D010979:Platelet Function Tests; D051381:Rats; D017208:Rats, Wistar; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D013997:Time Factors; D014680:Veins
D006493:Heparin